Immune-Related lncRNA Risk Signatures Predict Survival of IDH Wild-Type and MGMT Promoter Unmethylated Glioblastoma

Abstract EN

Introduction.

Glioblastoma is the most malignant grade of glioma, and it is also the most common primary tumor in the brain.

Immunotherapy is a kind of precise tumor treatment.

However, there are limited studies about immune-related lncRNA.

This study is aimed at analyzing immune-related lncRNAs in glioblastoma and screening out prognostic factors, providing new potential targets for glioblastoma immunology research.

Material and Methods.

Gene expression data and clinical data of IDH wild-type with MGMT promoter unmethylated glioblastoma were acquired from the TCGA and CGGA databases.

Immune-related lncRNAs were identified with the help of data from the InnateDB database.

Immune prognostic factors were recognized by Cox regression analysis.

GSEA analysis pursued their potential functions.

Results.

We found 318 immune-related lncRNAs.

Among them, there were 137 immune-related lncRNAs that were upregulated and 181 that were downregulated.

15 prognostic lncRNAs were identified by Cox regression, and a total of 6 molecules were included in the following risk scoring model.

GSEA showed that these lncRNAs participated in functions such as protein digestion and absorption and the PPAR signaling pathway.

Conclusion.

There are limited studies about immune regulation mechanisms of lncRNA in IDH wild-type with MGMT promoter unmethylated glioblastoma.

The identified immune-related lncRNAs in glioblastoma might contribute new targets and research directions for immunological molecular studies of glioblastoma.